Abstract

Axsome Therapeutics will release quarterly results on August 10, 2026, Pre-MKt; this preview synthesizes consensus expectations, company segment dynamics, and recent product developments to frame likely revenue, margin, and EPS outcomes for the current reporting period.

Market Forecast

Consensus and current-quarter forecasting point to total revenue of 221.03 million US dollars, up 59.29% year over year, with adjusted EPS of -0.84 improving 23.06% year over year; EBIT is estimated at -42.96 million US dollars, improving 15.28% year over year, while formal guidance for gross margin and net margin is not available. The main business remains product sales, which constituted 189.40 million US dollars last quarter, and consensus expects continued scale benefits from the commercial portfolio behind the revenue growth outlook. Within the portfolio, Auvelity is widely viewed as the most promising growth engine; its revenues sit within the products line (189.40 million US dollars last quarter), and analyst commentary anticipates ongoing year-over-year expansion tied to uptake in major depressive disorder and label progress in Alzheimer’s agitation.

Last Quarter Review

Axsome Therapeutics reported revenue of 191.20 million US dollars, up 57.42% year over year, with a gross profit margin of 92.30%, a GAAP net loss attributable to the parent company of -64.54 million US dollars, a net profit margin of -33.76%, and adjusted EPS of -1.26, declining 3.28% year over year. Net profit deteriorated quarter over quarter by 126% on the ran_on_month_change measure, reflecting operating investment intensity and commercial scaling costs. Main business highlights: product sales contributed 189.40 million US dollars and royalties 1.80 million US dollars; total revenue rose 57.42% year over year, underscoring broad portfolio expansion within the products line.

Current Quarter Outlook

Main Business: Commercial Products

Product sales are the financial center of Axsome Therapeutics and accounted for 189.40 million US dollars in the prior quarter, or approximately 99.06% of total revenue. With consensus revenue at 221.03 million US dollars for the current quarter and year-over-year growth of 59.29%, the trajectory implies continued volume gains and market-share capture from existing brands. The exceptionally high gross profit margin of 92.30% last quarter indicates a product mix with favorable pricing and cost of goods sold, which should help cushion operating expenses even as commercialization costs scale. Management’s adjusted EPS outcome last quarter of -1.26 and consensus for -0.84 this quarter signal improvement in per-share economics, aided by operating leverage from higher top-line, although SG&A and R&D deployment remain crucial to the near-term loss profile. Royalties contributed 1.80 million US dollars last quarter and are not expected to materially swing the quarter; the earnings cadence therefore hinges overwhelmingly on prescription trends and payer coverage for the commercial products portfolio.

Most Promising Business: Auvelity Growth and Label Expansion

Auvelity continues to be highlighted by covering analysts as the lead growth driver within Axsome Therapeutics’ marketed portfolio. Commentary emphasizes momentum in major depressive disorder and growing attention following its approval in Alzheimer’s agitation, which is expected to improve patient access and expand volume potential. While the company does not break out Auvelity revenue separately, the product’s trajectory is embedded within the products line that reached 189.40 million US dollars last quarter; consensus expects that strength to be a central contributor to the 221.03 million US dollars current-quarter revenue projection. The scale of uplift from new indications typically takes several quarters to flow through, as physician education, payer dynamics, and patient onboarding evolve; near term, investors will monitor prescription growth curves and any qualitative updates from management to gauge the depth of demand. With adjusted EPS estimated to improve 23.06% year over year to -0.84, continued Auvelity adoption and mix effects could be meaningful drivers of the quarter’s EPS delta versus last year, provided promotional investments do not offset margin gains.

Key Stock Price Drivers This Quarter

Three operational levers are most likely to influence Axsome Therapeutics’ share price around the print: top-line delivery versus consensus, margin progression, and updates on product and pipeline catalysts. First, a reported revenue outcome near the 221.03 million US dollars consensus would validate recent commercial execution; any meaningful deviation—positive or negative—could drive immediate volatility. Second, while formal gross margin and net margin guidance is not available, last quarter’s 92.30% gross margin sets a high bar; investors will parse commentary for mix shifts, pricing, and cost trends that could impact margins, and will tie those signals to the adjusted EPS trajectory from -1.26 last quarter to a forecasted -0.84 this quarter. Third, product and pipeline catalysts remain central to valuation: recent settlement resolving all Sunosi patent litigation reinforces exclusivity into the next decade and reduces legal overhang; at the same time, clinical progress with solriamfetol in attention deficit hyperactivity disorder (children and adolescents) and the FDA acceptance of the AXS-12 new drug application for cataplexy in narcolepsy add optionality to medium-term growth. The net of these factors is that execution on commercial products and clarity on operating costs are likely to outweigh pipeline timing effects in shaping near-term share reaction.

Analyst Opinions

Bullish perspectives dominate recent analyst commentary, with a clear ratio in favor of positive views relative to negative ones over the January to August 2026 window. Mizuho Securities reiterated its positive stance on Axsome Therapeutics, maintaining a Buy rating with a price target first at 310 US dollars and later modestly trimming to 306 US dollars, reflecting confidence in the commercial trajectory while acknowledging typical target recalibration as models refresh. RBC Capital maintained an Outperform rating and lifted its price target to 304 US dollars, a signal that execution and product momentum continue to track ahead of prior expectations in their model. Jefferies reaffirmed a Buy rating with a 245 US dollars price target, highlighting sustained progress across commercial operations and late-stage programs that underpin multi-quarter growth visibility. TD Cowen sustained a Buy rating and emphasized Auvelity’s best-in-class potential in Alzheimer’s agitation, framing the product as a cornerstone value driver for Axsome Therapeutics that can expand clinical utility and market reach. William Blair kept its Buy rating, citing solid execution, a sufficient cash runway, and advancing late-stage assets, which collectively support both the current commercialization phase and development milestones. BMO Capital initiated with an Outperform rating and a 310 US dollars price target, aligning with the broader bullish cohort that views Axsome Therapeutics’ portfolio and pipeline as supportive of above-market growth expectations.

Across these institutions, the majority view centers on several consistent themes that map directly to the current quarter setup. First, the predicted 59.29% year-over-year revenue increase to 221.03 million US dollars is seen as achievable due to expanding utilization of existing products, with Auvelity frequently cited as the pivotal contributor to top-line velocity. Second, margin durability is expected to be supported by the company’s product economics, evidenced by the 92.30% gross margin posted last quarter, even as salesforce expansion and promotional investments remain necessary to drive uptake. Third, pipeline events and IP clarity—specifically, the Sunosi patent litigation settlement and the FDA acceptance of the AXS-12 new drug application—are interpreted as de-risking elements that improve the probability-weighted value of future contributions without imposing unexpected near-term costs. Analysts, while attentive to operating expense levels and the timing of pipeline readouts, generally frame adjusted EPS improvement to -0.84 this quarter as consistent with higher revenue throughput and incremental operating leverage.

The bullish cohort also underscores the significance of upcoming label and geographic expansions in shaping medium-term estimates. For Auvelity, the Alzheimer’s agitation indication is frequently cited as a strategic lever to grow addressable market, which could translate to sustained double-digit year-over-year revenue growth embedded within the products line as coverage matures. For Sunosi, the resolution of patent disputes removes litigation uncertainty and supports steady commercial planning, while the attention deficit hyperactivity disorder Phase 3 programs with solriamfetol in children and adolescents are viewed as forward-looking avenues to broaden the therapeutic footprint; although the trials will not immediately impact this quarter’s revenue, their progression contributes to a constructive multi-year narrative that analysts factor into valuations. The aggregated view across these institutions is that Axsome Therapeutics’ portfolio depth, execution on commercial assets, and the cadence of development milestones together support the likelihood of meeting or modestly exceeding current-quarter revenue and EPS forecasts.

In terms of how this majority view ties to the immediate earnings preview, bullish analysts will judge the quarter on three scorecards: realized prescription trends against internal tracking, commentary around costs and margin sustainability, and tangible updates that validate ongoing product momentum. A revenue print close to 221.03 million US dollars, combined with signs that adjusted EPS is converging toward the -0.84 forecast, should be sufficient to maintain confidence in upwardly-biased outer-quarter estimates. Conversely, any unexpected weakness in product sell-through or sharp increases in operating expenses would likely prompt model adjustments, but the prevailing opinion is that commercial growth and IP/pipeline clarity can offset typical execution noise. Taken together, the majority institutional stance anticipates a constructive quarter for Axsome Therapeutics, with revenue acceleration and improving per-share metrics anchored by the company’s commercial portfolio and reinforced by de-risked IP and advancing late-stage assets.